Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Rating of “Hold” from Analysts

Smith & Nephew SNATS, Inc. (NYSE:SNN) has earned a consensus rating of “Hold” from the six brokerages that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $30.9250.

A number of research analysts have recently weighed in on SNN shares. The Goldman Sachs Group reissued a “buy” rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Canaccord Genuity Group dropped their price objective on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research note on Monday, May 11th. Weiss Ratings cut shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, June 11th. Sanford C. Bernstein set a $31.85 price objective on shares of Smith & Nephew SNATS in a research note on Monday, May 11th. Finally, Kepler Capital Markets cut shares of Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a research note on Thursday, June 4th.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock opened at $30.11 on Friday. Smith & Nephew SNATS has a 12-month low of $28.78 and a 12-month high of $38.79. The company has a quick ratio of 1.25, a current ratio of 2.57 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average of $31.09 and a two-hundred day moving average of $32.73.

Smith & Nephew SNATS (NYSE:SNN) last issued its earnings results on Tuesday, February 17th. The medical equipment provider reported $29.55 earnings per share (EPS) for the quarter. The company had revenue of $1.60 billion during the quarter. Analysts expect that Smith & Nephew SNATS will post 2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Paradigm Asset Management Co. LLC acquired a new position in shares of Smith & Nephew SNATS in the 3rd quarter valued at $1,502,000. Todd Asset Management LLC acquired a new position in shares of Smith & Nephew SNATS in the 3rd quarter valued at $26,319,000. Citigroup Inc. boosted its holdings in shares of Smith & Nephew SNATS by 44.8% in the 3rd quarter. Citigroup Inc. now owns 486,661 shares of the medical equipment provider’s stock valued at $17,661,000 after purchasing an additional 150,517 shares during the last quarter. Factory Mutual Insurance Co. acquired a new position in shares of Smith & Nephew SNATS in the 3rd quarter valued at $1,007,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in shares of Smith & Nephew SNATS in the 3rd quarter valued at $16,501,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.